At Viralgen, we’re tackling one of the biggest challenges in gene therapy manufacturing: scaling AAV production from research to GMP. By analyzing historical data and applying percentile-based modeling, our team developed a predictive approach that reduces scale-up variability and improves production planning.
This method provides a data-driven way to anticipate yields and optimize processes earlier—minimizing risks and supporting more reliable gene therapy delivery.
Learn more about our findings in our poster: “Leveraging Historical Data and Percentile-Based Modeling for Improved AAV Production Scaling.”
